Obesity doctor Spencer Nadolsky posts a short clip naming three common errors he sees among people taking GLP-1 medications.
Recap by typeshit. Post by Dr. Spencer Nadolsky on X.
He describes a case where a product sourced from neither Eli Lilly nor a compounding pharmacy was followed by liver failure within six days.
The pharmacists' group says the drug looks promising but urges patients to understand what they risk with unofficial sources, and points to its SafeMedication site.
The pharmacists' group points people to its SafeMedication site for a patient-friendly explainer on retatrutide and why unofficial sources are risky.
He says the woman's retatrutide came from neither Lilly nor a compounding pharmacy, and her liver failed within six days of starting it.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
10:08
Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
Loading…